Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1V-Fend----1件: 299
2V08CA02----1件: 13
3V08CA09----1件: 13
4V1512----1件: 6
5V1512 and Entacapone1件: Entacapone1件: D00781 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
6V565----2件: 96, 97
7V81444----1件: 6
8VA----3件: 90, 301, 302
9Vaccin grippal pandémique H1N1----1件: 299
10Vaccination----1件: 49
11Vaccination against TBE----1件: 46
12Vaccination with vaccine against hepatitis A and B----1件: 299
13Vaccine----1件: 49
14Vaccine Vivotif + Vaccine Dukoral2件: Recombinant Cholera Toxin B Subunit,
Typhoid Vaccine Live		---1件: 97
15Vaccine Vivotif + Vaccine Dukoral + oats3件: Oat,
Recombinant Cholera Toxin B Subunit,
Typhoid Vaccine Live		---1件: 97
16VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B----3件: 61, 62, 66
17VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO----2件: 61, 62
18VACCINO PNEUMOCOCCICO----2件: 62, 66
19VACCINO PNEUMOCOCCICO SACCARIDICO----1件: 14
20VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)----3件: 61, 62, 66
21Vaginal estriol1件: Estriol2件: D00185 ,
D01986 		2件: ESR1,
ESR2 💬		10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 13
22VAL-1221----1件: 256
23Valacyclovir1件: Valaciclovir3件: D00398 ,
D08664 ,
D10518 		--1件: 65
24Valbenazine1件: Valbenazine1件: D10675 1件: SLC18A2 💬7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Serotonergic synapse, Synaptic vesicle cycle 💬1件: 8
25Valdecoxib1件: Valdecoxib1件: D02709 1件: PTGS2 💬22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 46
26Valerian1件: Valerian---1件: 6
27Valganciclovir1件: Valganciclovir1件: D02495 --6件: 28, 60, 85, 97, 299, 331
28Valganciclovir (VGC)1件: Valganciclovir1件: D02495 --1件: 331
29Valganciclovir [Valcyte]1件: Valganciclovir1件: D02495 --1件: 299
30Valiloxybate----1件: 6
31Valproate1件: Valproic acid1件: D00399 7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬6件: 2, 3, 90, 102, 233, 256
32VALPROATE SODIUM1件: Valproic acid1件: D00399 7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 3
33Valproate, Levocarnitine2件: Levocarnitine,
Valproic acid		4件: D00399 ,
D02030 ,
D02176 ,
D04713 		7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 3
34Valproic Acid1件: Valproic acid1件: D00399 7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬10件: 3, 5, 26, 34, 65, 89, 90, 222, 256, 331
35Valproic Acid (VPA)1件: Valproic acid1件: D00399 7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 3
36Valproic Acid and Levocarnitine2件: Levocarnitine,
Valproic acid		4件: D00399 ,
D02030 ,
D02176 ,
D04713 		7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 3
37Valproid acid plus corticosteroids----1件: 26
38Valsartan1件: Valsartan1件: D00400 1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬7件: 57, 58, 66, 75, 218, 222, 224
39Vamarolone----1件: 113
40Vaminolac----1件: 97
41Vaminolac, komb.----1件: 97
42Vamorolone1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 97, 113
43Vamorolone 0.25 mg/day/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
44Vamorolone 0.25 mg/kg/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
45Vamorolone 0.75 mg/day/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
46Vamorolone 0.75 mg/kg/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
47Vamorolone 2.0 mg/day/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
48Vamorolone 2.0 mg/kg/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
49Vamorolone 4% suspension for oral dosing1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
50Vamorolone 6.0 mg/day/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
51Vamorolone 6.0 mg/kg/day1件: Vamorolone1件: D11000 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
52Vancomycin1件: Vancomycin2件: D00212 ,
D00926 		--7件: 46, 70, 94, 96, 97, 296, 299
53Vancomycin hydrochloride inhalation powder1件: Vancomycin2件: D00212 ,
D00926 		--1件: 299
54Vancomycin inhalation powder1件: Vancomycin2件: D00212 ,
D00926 		--1件: 299
55Vancomycin Pre-Treat1件: Vancomycin2件: D00212 ,
D00926 		--1件: 97
56Vancomycin Pre-Treatment1件: Vancomycin2件: D00212 ,
D00926 		--1件: 97
57Vanguard 360 TiNbN Femur with PS bearing----1件: 46
58Vanguard 360 TiNbN Femur with PSC bearing----1件: 46
59Vanguard DA 360----1件: 46
60Vanguard SSK 360 with PS Bearing----1件: 46
61Vanguard SSK 360 with PSC bearing----1件: 46
62Vantobra (tobramycin)1件: Tobramycin2件: D00063 ,
D02542 		--1件: 299
63Vardenafil1件: Vardenafil3件: D02731 ,
D03260 ,
D08668 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 13, 86, 299
64Vardenafil (hidrocloride)1件: Vardenafil3件: D02731 ,
D03260 ,
D08668 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 13
65Vardenafilo1件: Vardenafil3件: D02731 ,
D03260 ,
D08668 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 13
66VARDENAFILO HIDROCLORURO1件: Vardenafil3件: D02731 ,
D03260 ,
D08668 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 13
67VARENICLINE1件: Varenicline1件: D08669 2件: CHRNA4,
CHRNB2 💬		4件: Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction 💬2件: 6, 18
68VARENICLINE TARTRATE1件: Varenicline1件: D08669 2件: CHRNA4,
CHRNB2 💬		4件: Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction 💬1件: 6
69VARI----2件: 62, 274
70Variation of behaviors of Parkinson's disease----1件: 6
71Varicella Zoster Vaccine----1件: 46
72Various----1件: 95
73Vaseline----1件: 51
74Vasoactive intestinal peptide----1件: 85
75Vasomera (PB1046) Injection----1件: 86
76Vasopressin1件: Vasopressin1件: D00101 3件: AVPR1A,
AVPR1B,
AVPR2 💬		5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬1件: 210
77Vasopressin, Arginine2件: Arginine,
Vasopressin		2件: D00101 ,
D02982 		3件: AVPR1A,
AVPR1B,
AVPR2 💬		5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬1件: 210
78Vastarel----2件: 2, 58
79Vastarel 20mg film coated tablets----1件: 58
80Vatelizumab1件: Vatelizumab---2件: 13, 97
81VATIQUINONE1件: Vatiquinone1件: D10407 --2件: 18, 21
82Vaxzevria1件: AstraZeneca COVID-19 Vaccine---1件: 299
83Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S1件: AstraZeneca COVID-19 Vaccine---1件: 299
84VAY736----7件: 13, 35, 46, 49, 53, 85, 95
85VAY736 antibody----1件: 53
86VAY736 higher dose----1件: 53
87VAY736 lower dose----1件: 53
88VB-2011件: VB-201---1件: 97
89VB-201 160mg1件: VB-201---1件: 97
90VB119----1件: 222
91VB13S1----1件: 13
92VB5S2----1件: 13
93VB6S5----1件: 13
94VBP15----1件: 113
95VE202----1件: 97
96Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana----1件: 19
97VEDOLIZUMAB1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬3件: 94, 96, 97
98Vedolizumab (Genetical Recombination)1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 96
99Vedolizumab 108 mg SC1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 97
100Vedolizumab 300 mg1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 97
101Vedolizumab 300 MG Injection [Entyvio]1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 96
102Vedolizumab 300 mg IV1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 97
103Vedolizumab Injection1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 97
104Vedolizumab Intravenous (IV), Vedolizumab Subcutaneous (SC), Placebo IV1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 97
105Vedolizumab intravenous injection1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬2件: 96, 97
106Vedolizumab IV1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬3件: 94, 96, 97
107Vedolizumab IV (Entyvio¿)1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 96
108Vedolizumab IV (Entyvio™)1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 96
109Vedolizumab IV 300 mg1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 96
110Vedolizumab IV, Placebo IV, Placebo SC1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 97
111Vedolizumab IV, Placebo SC1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 97
112Vedolizumab SC1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬2件: 96, 97
113Vedolizumab SC 108 mg1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬2件: 96, 97
114Vedolizumab subcutaneous injection1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬2件: 96, 97
115Vedolizumab, Ustekinumab, or Tofacitinib3件: Tofacitinib,
Ustekinumab,
Vedolizumab		3件: D08083 ,
D09214 ,
D09970 		9件: IL12A,
IL12B,
IL23A,
ITGA4,
ITGB7,
JAK1,
JAK2,
JAK3,
TYK2 💬		65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Focal adhesion, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pertussis, Primary immunodeficiency, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Yersinia infection 💬1件: 97
116Vedolizumab-800CW1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 96
117VEDROP1件: Tocofersolan1件: D06174 --1件: 299
118VEDULIZUMAB----1件: 97
119Vehice Control----1件: 96
120Vehicle----4件: 6, 36, 160, 192
121Vehicle (SD-101 0%)----1件: 36
122Vehicle Control----1件: 53
123Vehicle Cream----1件: 36
124Vehicle eye drops----1件: 90
125Vehicle Gel----2件: 13, 34
126Vehicle of ADX-102 Topical Dermal Cream----1件: 160
127Vehicle ophthalmic solution----1件: 53
128Vehicle Topical Gel----1件: 36
129VELAGLUCERASE ALFA1件: Velaglucerase alfa1件: D09029 1件: GBA 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19
130Velaglucerase alfa (VPRIV)1件: Velaglucerase alfa1件: D09029 1件: GBA 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19
131Velaglucerasi alfa----1件: 19
132Velamox----1件: 11
133Velcade1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬3件: 11, 28, 61
134VELCADE*1FL 3,5MG1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 28
135VELCADE*EV 1FL 3,5MG 1MG/ML1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 61
136Velcade®1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 11
137Veldona----1件: 56
138Veldona,----1件: 56
139Veledimex1件: Veledimex1件: D10678 --1件: 51
140Veletri1件: Epoprostenol2件: D00106 ,
D01337 		1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
141VELMANASE ALFA1件: Velmanase alfa1件: D11024 1件: MAN2B1 💬2件: Lysosome, Other glycan degradation 💬1件: 19
142Velmanase Alfa (e.g. Lamazym)1件: Velmanase alfa1件: D11024 1件: MAN2B1 💬2件: Lysosome, Other glycan degradation 💬1件: 19
143Veltuzumab1件: Veltuzumab1件: D09031 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
144Veltuzumab solution 75mg/ml1件: Veltuzumab1件: D09031 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
145Velusetrag1件: Velusetrag1件: D09693 1件: HTR4 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway 💬1件: 99
146Venetoclax1件: Venetoclax1件: D10679 1件: BCL2 💬43件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Autophagy - animal, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Epstein-Barr virus infection, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, HIF-1 signaling pathway, Hedgehog signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Lipid and atherosclerosis, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prostate cancer, Protein processing in endoplasmic reticulum, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, Toxoplasmosis, Tuberculosis, p53 signaling pathway 💬1件: 28
147Venglustat1件: Venglustat1件: D11633 1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬3件: 6, 19, 67
148Venglustat (GZ402671)1件: Venglustat1件: D11633 1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬1件: 19
149Venglustat GZ/SAR4026711件: Venglustat1件: D11633 1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬2件: 6, 67
150Venglustat GZ4026711件: Venglustat1件: D11633 1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬2件: 19, 67
151Venglustat malate1件: Venglustat1件: D11633 1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬3件: 6, 19, 67
152Venglustat malato1件: Venglustat1件: D11633 1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬2件: 19, 67
153Venipunctures----1件: 84
154Venlafaxin Hexal----1件: 13
155Venlafaxine1件: Venlafaxine2件: D00821 ,
D08670 		2件: SLC6A2,
SLC6A4 💬		2件: Serotonergic synapse, Synaptic vesicle cycle 💬3件: 6, 13, 46
156VENLAFAXINE HYDROCHLORIDE1件: Venlafaxine2件: D00821 ,
D08670 		2件: SLC6A2,
SLC6A4 💬		2件: Serotonergic synapse, Synaptic vesicle cycle 💬2件: 13, 46
157Venous blood sample----1件: 46
158Ventavis1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
159Ventavis (Iloprost, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
160Ventavis 101件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
161Ventavis(Iloprost)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
162Ventolin1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 299
163Ventoline----1件: 111
164Ventoline oral solution 0,4mg/ml----1件: 111
165Ventoline tablet 2mg----1件: 111
166Ventolin® Evohaler1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 299
167Ventolin¿ Evohaler¿1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 299
168Venus Versa----1件: 265
169Verapamil1件: Verapamil2件: D00619 ,
D02356 		4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 96, 140, 167
170Verapamil SR1件: Verapamil2件: D00619 ,
D02356 		4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 167
171Verde de Indocianina (Indocyanine Green)1件: Indocyanine green1件: D01342 --1件: 235
172Verdiperstat1件: Verdiperstat1件: D11684 1件: MPO 💬5件: Acute myeloid leukemia, Drug metabolism - other enzymes, Neutrophil extracellular trap formation, Phagosome, Transcriptional misregulation in cancer 💬3件: 2, 17, 127
173Veregen1件: Sinecatechins1件: D08997 --1件: 160
174VEREGEN(R)1件: Sinecatechins1件: D08997 --1件: 160
175Verorab® (PVRV----1件: 65
176Versus hydroxychloroquine1件: Hydroxychloroquine1件: D08050 --1件: 49
177Verum arm receiving Gilenya®----1件: 13
178Verum arm receiving Vitamin D oil1件: Vitamin D---1件: 13
179VESANOID1件: Tretinoin1件: D00094 3件: PML,
RARA,
RARB 💬		12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 75
180VESIcare 10Mg Tablet----1件: 13
181Vessel----4件: 13, 51, 271, 288
182Vestronidase alfa1件: Vestronidase alfa1件: D11004 1件: GUSB 💬8件: Ascorbate and aldarate metabolism, Biosynthesis of cofactors, Drug metabolism - other enzymes, Glycosaminoglycan degradation, Lysosome, Metabolic pathways, Pentose and glucuronate interconversions, Porphyrin metabolism 💬1件: 19
183Vett Lentiviral con gene ABCA4----1件: 301
184VEYONDI 650IU powder and solvent for solution for injection----1件: 288
185Veyvondi1件: Vonicog alfa1件: D08681 --1件: 288
186VEYVONDI 1300I IU powder and solvent for solution for injection1件: Vonicog alfa1件: D08681 --1件: 288
187VEYVONDI 1300IU powder and solvent for solution for injection1件: Vonicog alfa1件: D08681 --1件: 288
188VEYVONDI 650IU powder and solvent for solution for injection1件: Vonicog alfa1件: D08681 --1件: 288
189Vfend1件: Voriconazole1件: D00578 --1件: 299
190VFEND 40 mg/ml powder for oral suspension1件: Voriconazole1件: D00578 --1件: 299
191VGB-ST----1件: 145
192VGB-ST soluble tablets----1件: 145
193VIAGRA1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 86, 96, 225
194VIALEBEX----1件: 96
195Vialebex 200mg----1件: 96
196Viaskin Milk 500 mcg1件: Cow milk---1件: 98
197VIB4920----2件: 46, 53
198VIB7734----4件: 49, 50, 51, 53
199VIB7734, MEDI7734----1件: 49
200VIBEX MTX----1件: 46
201Vibrox----1件: 167
202Vibrox 100mg Capsules----1件: 167
203Video calling program Better-close----1件: 13
204Video game therapy----1件: 13
205Videofluoroscopic Swallowing Study----1件: 2
206Videofluoroscopic Swallowing Study (VFSS)----1件: 2
207Vidofludimus1件: Vidofludimus---5件: 13, 46, 94, 96, 97
208VIDOFLUDIMUS CALCIUM2件: Calcium,
Vidofludimus		---4件: 13, 94, 96, 97
209Vidofludimus calcium dihydrate2件: Calcium,
Vidofludimus		---1件: 97
210VIGABATRIN1件: Vigabatrin1件: D00535 1件: ABAT 💬7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬2件: 145, 158
211Vigabatrin (Sabril)1件: Vigabatrin1件: D00535 1件: ABAT 💬7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 158
212Vigabatrin Tablets1件: Vigabatrin1件: D00535 1件: ABAT 💬7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 145
213Vigabatrin: Vigabatrin new ST formulation then Sabril®1件: Vigabatrin1件: D00535 1件: ABAT 💬7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 145
214Vigantol----4件: 13, 65, 96, 97
215Vigantol Oel----3件: 13, 96, 97
216Vigantol Oel TM----2件: 96, 97
217VIGANTOL OIL----1件: 13
218VigantOL oil plus interferon beta-1a (Rebif)2件: Human interferon beta,
Interferon beta-1a		1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
219Vigantol® Oil----1件: 13
220Vigantol® Öl 20.000 I.E./ml----1件: 13
221Vilobelimab1件: Vilobelimab1件: D11838 1件: C5 💬10件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬2件: 43, 44
222VILTOLARSEN1件: Viltolarsen1件: D11528 1件: DMD 💬4件: Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬1件: 113
223Vimizim® (elosulfase alfa)1件: Elosulfase alfa1件: D10333 1件: GALNS 💬3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬1件: 19
224VIMOVO 250/20----1件: 107
225VIMOVO 375/20----1件: 107
226VIMOVO 500/20----1件: 107
227Vinblastine1件: Vinblastine2件: D01068 ,
D08675 		9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬2件: 34, 65
228Vinblastine sulfate2件: Sulfate ion,
Vinblastine		2件: D01068 ,
D08675 		9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 34
229VINBLASTINE SULPHATE1件: Vinblastine2件: D01068 ,
D08675 		9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 34
230Vinblastine, vincristine, prednisone, daunorubicin4件: Daunorubicin,
Prednisone,
Vinblastine,
Vincristine		7件: D00473 ,
D01068 ,
D01264 ,
D02197 ,
D07776 ,
D08675 ,
D08679 		12件: NR3C1,
TOP2A,
TOP2B,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬1件: 65
231Vincristine1件: Vincristine2件: D02197 ,
D08679 		9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬4件: 26, 34, 65, 331
232Vincristine Sulfate2件: Sulfate ion,
Vincristine		2件: D02197 ,
D08679 		9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬2件: 26, 34
233Vincristine Sulfate (Oncovin)2件: Sulfate ion,
Vincristine		2件: D02197 ,
D08679 		9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 34
234ViNeuro----1件: 6
235VIOKASE 16----1件: 298
236Viokase 16 (pancrelipase) + Nexium2件: Esomeprazole,
Pancrelipase		5件: D01984 ,
D04056 ,
D05349 ,
D07917 ,
D09339 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 298
237Viokase® 16----1件: 298
238VIP----3件: 49, 51, 86
239Viral load driven treatment interruption----1件: 265
240VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE----1件: 46
241VIREAD 30 CPR 245 MG----1件: 46
242VIS649----1件: 66
243Viscous/swallowed budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
244Visilizumab1件: Visilizumab1件: D06314 3件: CD3D,
CD3E,
CD3G 💬		11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬2件: 96, 97
245Visilizumab (Nuvion)1件: Visilizumab1件: D06314 3件: CD3D,
CD3E,
CD3G 💬		11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 97
246VISMODEGIB1件: Vismodegib1件: D09992 1件: SMO 💬5件: Axon guidance, Basal cell carcinoma, Hedgehog signaling pathway, Pathways in cancer, Proteoglycans in cancer 💬1件: 85
247Visual field testing----1件: 19
248Vit C Vit E Zn Se----1件: 113
249Vit D----1件: 227
250Vitamin A1件: Vitamin A2件: D00069 ,
D06543 		2件: RARA,
RARB 💬		8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬3件: 13, 53, 90
251Vitamin AD sig: 1 tablet/tid----1件: 90
252Vitamin B sig: 10mg/tid----1件: 90
253Vitamin B11件: Thiamine1件: D08580 --1件: 145
254Vitamin B121件: Cyanocobalamin4件: D00166 ,
D03615 ,
D03616 ,
D03617 		--4件: 6, 201, 229, 299
255Vitamin B12 Supplementation1件: Cyanocobalamin4件: D00166 ,
D03615 ,
D03616 ,
D03617 		--1件: 6
256Vitamin B12, B9, B6, C supplementation1件: Cyanocobalamin4件: D00166 ,
D03615 ,
D03616 ,
D03617 		--1件: 229
257Vitamin B21件: Riboflavin3件: D00050 ,
D01622 ,
D01913 		--1件: 97
258Vitamin B3----2件: 65, 107
259Vitamin B61件: Pyridoxine2件: D02179 ,
D08454 		--2件: 6, 206
260Vitamin B71件: Biotin1件: D00029 --1件: 8
261Vitamin C1件: Ascorbic acid1件: D00018 --6件: 10, 192, 206, 210, 211, 212
262Vitamin C 10mg/Kg Vitamin E 10 mg/Kg2件: Ascorbic acid,
Vitamin E		2件: D00018 ,
D02331 		--1件: 206
263Vitamin D1件: Vitamin D---24件: 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299
264Vitamin D 100ug1件: Vitamin D---1件: 298
265Vitamin D 10ug1件: Vitamin D---1件: 298
266Vitamin D 21件: Vitamin D---1件: 46
267Vitamin D 25(OH)D1件: Vitamin D---1件: 49
268Vitamin D drops1件: Vitamin D---2件: 96, 97
269Vitamin D in arm B1件: Vitamin D---1件: 46
270Vitamin D Oil1件: Vitamin D---1件: 299
271Vitamin D Powder1件: Vitamin D---1件: 299
272Vitamin D21件: Ergocalciferol1件: D00187 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬3件: 49, 84, 299
273Vitamin D2 ( calciferol )2件: Ergocalciferol,
Vitamin D		1件: D00187 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 49
274Vitamin D31件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬12件: 6, 13, 20, 46, 49, 51, 53, 60, 65, 96, 97, 299
275Vitamin D3 - high dose1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 6
276Vitamin D3 3000 UI daily1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96
277Vitamin D3 400 IU1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 49
278Vitamin D3 4000 UI daily1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96
279Vitamin D3 6000 IU1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 49
280Vitamin D3 800 UI/day then 800 UI/day1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96
281Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96
282Vitamin E1件: Vitamin E1件: D02331 --11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317
283VITAMIN E - TGPS1件: Vitamin E1件: D02331 --1件: 299
284Vitamin E 800IU1件: Vitamin E1件: D02331 --2件: 96, 97
285Vitamin E supplement1件: Vitamin E1件: D02331 --1件: 317
286Vitamin E/Selenium2件: Selenium,
Vitamin E		1件: D02331 --1件: 13
287Vitamin K1件: Phylloquinone1件: D00148 --5件: 13, 46, 96, 97, 299
288Vitamin K 10 mg1件: Phylloquinone1件: D00148 --2件: 96, 97
289Vitamin K supplementation, dose #11件: Phylloquinone1件: D00148 --1件: 299
290Vitamin K supplementation, dose #21件: Phylloquinone1件: D00148 --1件: 299
291Vitamin K11件: Phylloquinone1件: D00148 --1件: 96
292Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:11件: Choline1件: D07690 --1件: 299
293Vitamina D e calcio1件: Calcium---1件: 274
294VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA----1件: 13
295Vitamins: B6, B12, and folate1件: Folic acid1件: D00070 --1件: 49
296VIUSID/ALZER----1件: 6
297Vivaglobin----2件: 14, 65
298ViviGen Cellular Bone Matrix----1件: 70
299Vivomixx probiotics----1件: 51
300Vivotif1件: Typhoid Vaccine Live---1件: 97
301Vizamyl1件: Flutemetamol (18F)---3件: 5, 7, 127
302Vizamyl (flutemetamol(F-18))1件: Flutemetamol (18F)---3件: 5, 7, 127
303VK0214----1件: 20
304VM106----1件: 65
305VM202----1件: 2
306VO4CX----1件: 296
307Vobarilizumab1件: Vobarilizumab1件: D11005 --1件: 49
308Voclosporin1件: Voclosporin1件: D09033 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222
309Volanesorsen1件: Volanesorsen1件: D11648 1件: APOC3 💬2件: Cholesterol metabolism, PPAR signaling pathway 💬1件: 265
310VOLANESORSEN SODIUM, ApoC-III Antisense Oligonucleotide1件: Volanesorsen1件: D11648 1件: APOC3 💬2件: Cholesterol metabolism, PPAR signaling pathway 💬1件: 265
311Volibris1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 51, 85, 86, 88
312VOLIBRIS 10 mg comprimidos recubiertos con película1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
313VOLIBRIS 5 mg comprimidos recubiertos con película1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
314VOLIBRIS® (ambrisentan)1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
315VOLIBRIS™ tablets1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
316Volixibat1件: Volixibat1件: D11007 --2件: 93, 94
317Volixibat (formely SHP626, LUM002 or SAR548304B)1件: Volixibat1件: D11007 --1件: 94
318Volixibat potassium2件: Potassium,
Volixibat		2件: D08403 ,
D11007 		--1件: 94
319VOLMAX*30CPR 4MG R.P.----1件: 3
320Voltaren resinat----1件: 271
321Voltarol----1件: 46
322Voltarol SR----1件: 46
323Voltarol SR (generics also available in the EU)----1件: 46
324Voltrarol SR----1件: 46
325Voluntary Peak Cough Flow Testing----1件: 2
326Von willebrand factor1件: Von Willebrand factor human---2件: 64, 288
327Von Willebrand factor (Recombinant)1件: Von Willebrand factor human---1件: 288
328Von Willebrand factor and coagulation factor VIII in combination2件: Beroctocog alfa,
Von Willebrand factor human		---1件: 288
329Von Willebrand Factor Antigen1件: Von Willebrand factor human---1件: 288
330Von Willebrand Factor Ristocetin Cofactor1件: Von Willebrand factor human---1件: 288
331Von Willebrand Faktor----1件: 288
332Voncento1件: Von Willebrand factor human---1件: 288
333Voncento, Biostate®1件: Von Willebrand factor human---1件: 288
334Voncento®1件: Von Willebrand factor human---1件: 288
335VONICOG ALFA1件: Vonicog alfa1件: D08681 --1件: 288
336Vonoprazan1件: Vonoprazan1件: D11784 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬2件: 63, 98
337Voriconazole1件: Voriconazole1件: D00578 --2件: 60, 299
338Vorinostat1件: Vorinostat1件: D06320 11件: HDAC1,
HDAC10,
HDAC11,
HDAC2,
HDAC3,
HDAC4,
HDAC5,
HDAC6,
HDAC7,
HDAC8,
HDAC9 💬		17件: Alcoholism, Amphetamine addiction, Amyotrophic lateral sclerosis, Apelin signaling pathway, Cell cycle, Chronic myeloid leukemia, Epstein-Barr virus infection, Human papillomavirus infection, Huntington disease, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, Notch signaling pathway, Pathways in cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Viral carcinogenesis 💬3件: 19, 75, 96
339Vorsoritide----1件: 276
340Vortioxetine1件: Vortioxetine1件: D10184 7件: HTR1A,
HTR3A,
HTR3B,
HTR3C,
HTR3D,
HTR3E,
SLC6A4 💬		5件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬1件: 6
341Vosoritide1件: Vosoritide1件: D11190 1件: NPR2 💬5件: Metabolic pathways, Oxytocin signaling pathway, Purine metabolism, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 276
342Votubia1件: Everolimus1件: D02714 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬2件: 34, 158
343VPA----1件: 3
344VPD-737----1件: 36
345VPRIV1件: Velaglucerase alfa1件: D09029 1件: GBA 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19
346VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO1件: Velaglucerase alfa1件: D09029 1件: GBA 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19
347VPRIV 400 Units powder for solution of infusion1件: Velaglucerase alfa1件: D09029 1件: GBA 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19
348VPRIV ®,1件: Velaglucerase alfa1件: D09029 1件: GBA 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19
349VPRIV®1件: Velaglucerase alfa1件: D09029 1件: GBA 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19
350VR040----1件: 6
351VR040/Aspirair® inhaler----1件: 6
352VR496----1件: 299
353VRP700----1件: 85
354VRS-317----1件: 78
355VRT-813077----1件: 299
356VRT-826809----1件: 299
357VRT-893661----1件: 299
358VRT-893661 VRT-0893661----1件: 299
359VSL#3----4件: 96, 97, 107, 291
360VSL#3 (Original De Simone formulation)----2件: 96, 97
361VSL#3®----2件: 96, 97
362VSN16R----1件: 13
363VSN16R 100mg----1件: 13
364VT-001----1件: 66
365VT30----2件: 278, 279
366VTS-270----1件: 19
367VTX-801----1件: 171
368VTX002----1件: 97
369VTX002 is not biologic----1件: 97
370VWD factor VIII concentrate1件: Beroctocog alfa---1件: 288
371VWF replacement therapy with Wilate1件: Von Willebrand factor human---1件: 288
372VWF SD-35-DH----1件: 288
373VWF-containing products----1件: 288
374VWF/FVIII products----1件: 288
375VX-121----1件: 299
376VX-121/TEZ/D-IVA----1件: 299
377VX-121/tezacaftor/deutivacaftor2件: Deutivacaftor,
Tezacaftor		2件: D11041 ,
D11423 		1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
378VX-147----1件: 222
379VX-152----1件: 299
380VX-371----1件: 299
381VX-371 in hypertonic saline----1件: 299
382VX-371 in saline----1件: 299
383VX-440----1件: 299
384VX-445----1件: 299
385VX-445 / TEZ / IVA----1件: 299
386VX-445 / TEZ / IVA FDC----1件: 299
387VX-445 /TEZ/IVA----1件: 299
388VX-445/TEZ/IVA----1件: 299
389VX-509----1件: 46
390VX-561----1件: 299
391VX-561 (CTP-656)----1件: 299
392VX-6591件: VX-659---1件: 299
393VX-659/ TEZ/IVA1件: VX-659---1件: 299
394VX-659/TEZ/IVA1件: VX-659---1件: 299
395VX-659/Tezacaftor/Ivacaftor3件: Ivacaftor,
Tezacaftor,
VX-659		2件: D09916 ,
D11041 		1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
396VX-661----1件: 299
397VX-661 / VX-770----1件: 299
398VX-661 Plus Ivacaftor Combination1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
399VX-661, VRT-893661----1件: 299
400VX-661/Ivacaftor1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
401VX-661/ivacaftor (VX-770) 100mg/150 mg1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
402VX-661/ivacaftor 100 mg/ 150 mg1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
403VX-661/ivacaftor 100mg/150 mg1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
404VX-661/ivacaftor 100mg/150mg1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
405VX-661/ivacaftor 50 mg/ 75 mg1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
406VX-661/VX-770----1件: 299
407VX-661/VX-770 (TEZ/IVA)----1件: 299
408VX-7021件: VX-702---1件: 46
409VX-745----1件: 8
410VX-77----1件: 299
411VX-770----1件: 299
412VX-770, VRT-8130077----1件: 299
413VX-770, VRT-813077----1件: 299
414VX-809----1件: 299
415VX-809 & VX-770----1件: 299
416VX-809 / VX-770----1件: 299
417VX-809, VRT-826809----1件: 299
418VX-809/VX-770----1件: 299
419VX-814----1件: 231
420VX-864----1件: 231
421VX147----1件: 222
422VX15/2503----2件: 8, 13
423VX864----1件: 231
424VY-AADC01----1件: 6
425VY-AADC02----1件: 6
426Vyndaqel1件: Tafamidis1件: D09673 1件: TTR 💬1件: Thyroid hormone synthesis 💬1件: 28
427Vyndaqel 20mg soft capsule1件: Tafamidis1件: D09673 1件: TTR 💬1件: Thyroid hormone synthesis 💬1件: 28
428Vyondys 531件: Golodirsen1件: D11707 1件: DMD 💬4件: Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬1件: 113